Orion Biotechnology Canada Ltd, a developer of novel medical treatments for chronic illness and life-threatening diseases, today announced a strategic partnership with the Center for Public Health Research (CPHR) and the State Key Laboratory of Analytical Chemistry (SKLAC) of Nanjing University. The partnership will focus on supporting the development of Orion’s China sourced biopharmaceutical solutions, including the company’s unique multipurpose microbicide candidate (OB-001) – a non-antiretroviral microbicide designed to be a contraceptive which also prevents the transmission of HIV.

“We are delighted to work with Nanjing University, one of the top academic centers in China,” said Mark Groper, President & CEO of Orion. “Orion is committed to sourcing and developing solutions for the China market. Our partnership with Nanjing University is an important step forward for our China program and we look forward to developing a strong and mutually beneficial relationship.” Orion has established a series of collaborations with leading universities and research institutes around the globe to facilitate more rapid identification and development of novel treatments for emerging health issues.

Nanjing University’s SKLAC and CPHR will collaborate with Orion in conducting research and development, pre-clinical testing and IND-enabling studies. Dr. Allen Wu, Professor and Associate Director of the SKLAC, expressed optimism and excitement about this collaboration. “Academic and industry collaborations help tackle the gap between fundamental scientific discovery and commercial application. We are pleased to be working closely with Orion, a very promising biotechnology company with excellent management and a strong R&D team. Our collaboration will focus initially on Orion’s unique HIV prevention solution – a large and growing unmet need medical need in China.”